- Email: [email protected]
Detection of Minimal Residual Disease in Autografts by Aso-Pcr for Patients with Multiple Myeloma
Annals of Oncology 25 (Supplement 5): v75–v109, 2014 doi:10.1093/annonc/mdu436.36
Poster Session (Poster presentations categorized by each organ) P1
19
1
Shigeki Ito1, Hiroyuki Takamatsu2, Takahiro Mine1, Tatsuo Oyake1, Kazunori Murai1, Yoji Ishida1 1 Hematology & Oncology, Department of Internal Medicine, Iwate Medical University 2 Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Sciences
abstracts
Background: The high-dose melphalan followed by autologous blood stem cell transplantation (ASCT) is a standard treatment for younger patients with multiple myeloma (MM). Recent reports have shown that achieving molecular complete response is associated with longer progression-free survival. However, the impact of minimal residual disease (MRD) in peripheral blood cell autografts on outcome
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v82/2240469 by guest on 26 October 2019
DETECTION OF MINIMAL RESIDUAL DISEASE IN AUTOGRAFTS BY ASO-PCR FOR PATIENTS WITH MULTIPLE MYELOMA
remains unknown. We report the clinical and molecular follow-up of 6 MM patients who underwent ASCT. Methods: Six patients in whom the treatment was performed at Iwate Medical University Hospital and MRD in autografts was evaluable were included in the study. All patients had achieved at least a partial response after ASCT. Fresh bone marrow cells at diagnosis as well as autografts were obtained for DNA extraction. The CDR III coding region of the IgH gene was studied by direct sequencing of PCR product from bone marrow samples at diagnosis, and then MRD in each autograft was measured by ASO-PCR. Results: Four of 6 patients are alive: 2 who had no MRD in their autografts maintain a stringent complete response (CR) for 40 and 8 months after ASCT, while 2 who had MRD in them have serum M protein assessable by immunofixation for 20 and 10 months after ASCT. Two patients died from disease progression, both of which had MRD in their autografts and had have serum M protein after ASCT. Conclusion: These observations suggest that no MRD in peripheral blood cell autografts may be associated with a durable CR after ASCT. In addition, the post-ASCT treatment such as consolidation or maintenance therapy should be considered for MM patients who have MRD in autografts. Larger study and serial follow-up should be recommended to establish the clinical impact of MRD measurement in autografts in MM patients. As of writing, follow-up MRD analyses for total 13 MM patients are ongoing. Updated results will be presented.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Poster Session (Poster presentations categorized by each organ) P1
19
1
Shigeki Ito1, Hiroyuki Takamatsu2, Takahiro Mine1, Tatsuo Oyake1, Kazunori Murai1, Yoji Ishida1 1 Hematology & Oncology, Department of Internal Medicine, Iwate Medical University 2 Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Sciences
abstracts
Background: The high-dose melphalan followed by autologous blood stem cell transplantation (ASCT) is a standard treatment for younger patients with multiple myeloma (MM). Recent reports have shown that achieving molecular complete response is associated with longer progression-free survival. However, the impact of minimal residual disease (MRD) in peripheral blood cell autografts on outcome
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v82/2240469 by guest on 26 October 2019
DETECTION OF MINIMAL RESIDUAL DISEASE IN AUTOGRAFTS BY ASO-PCR FOR PATIENTS WITH MULTIPLE MYELOMA
remains unknown. We report the clinical and molecular follow-up of 6 MM patients who underwent ASCT. Methods: Six patients in whom the treatment was performed at Iwate Medical University Hospital and MRD in autografts was evaluable were included in the study. All patients had achieved at least a partial response after ASCT. Fresh bone marrow cells at diagnosis as well as autografts were obtained for DNA extraction. The CDR III coding region of the IgH gene was studied by direct sequencing of PCR product from bone marrow samples at diagnosis, and then MRD in each autograft was measured by ASO-PCR. Results: Four of 6 patients are alive: 2 who had no MRD in their autografts maintain a stringent complete response (CR) for 40 and 8 months after ASCT, while 2 who had MRD in them have serum M protein assessable by immunofixation for 20 and 10 months after ASCT. Two patients died from disease progression, both of which had MRD in their autografts and had have serum M protein after ASCT. Conclusion: These observations suggest that no MRD in peripheral blood cell autografts may be associated with a durable CR after ASCT. In addition, the post-ASCT treatment such as consolidation or maintenance therapy should be considered for MM patients who have MRD in autografts. Larger study and serial follow-up should be recommended to establish the clinical impact of MRD measurement in autografts in MM patients. As of writing, follow-up MRD analyses for total 13 MM patients are ongoing. Updated results will be presented.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].